LepRb+ cell-specific deletion of Slug mitigates obesity and nonalcoholic fatty liver disease in mice.
| Citation | Kim, Min-Hyun, et al. “LepRb+ Cell-Specific Deletion of Slug Mitigates Obesity and Nonalcoholic Fatty Liver Disease in Mice”. 2023. The Journal of Clinical Investigation, vol. 133, no. 4, 2023.  | 
       
| Center | University of Michigan | 
| Author | Min-Hyun Kim, Yuan Li, Qiantao Zheng, Lin Jiang, Martin G Myers, Wen-Shu Wu, Liangyou Rui | 
| Keywords | Cell Biology, diabetes, leptin, Metabolism, obesity | 
| Abstract | 
   Leptin exerts its biological actions by activating the long-form leptin receptor (LepRb). LepRb signaling impairment and leptin resistance are believed to cause obesity. The transcription factor Slug - also known as Snai2 - recruits epigenetic modifiers and regulates gene expression by an epigenetic mechanism; however, its epigenetic action has not been explored in leptin resistance. Here, we uncover a proobesity function of neuronal Slug. Hypothalamic Slug was upregulated in obese mice. LepRb+ cell-specific Slug-knockout (SlugΔLepRb) mice were resistant to diet-induced obesity, type 2 diabetes, and liver steatosis and experienced decreased food intake and increased fat thermogenesis. Leptin stimulated hypothalamic Stat3 phosphorylation and weight loss to a markedly higher level in SlugΔLepRb than in Slugfl/fl mice, even before their body weight divergence. Conversely, hypothalamic LepRb+ neuron-specific overexpression of Slug, mediated by AAV-hSyn-DIO-Slug transduction, induced leptin resistance, obesity, and metabolic disorders in mice on a chow diet. At the genomic level, Slug bound to and repressed the LepRb promoter, thereby inhibiting LepRb transcription. Consistently, Slug deficiency decreased methylation of LepRb promoter H3K27, a repressive epigenetic mark, and increased LepRb mRNA levels in the hypothalamus. Collectively, these results unravel what we believe to be a previously unrecognized hypothalamic neuronal Slug/epigenetic reprogramming/leptin resistance axis that promotes energy imbalance, obesity, and metabolic disease.  | 
        
| Year of Publication | 
   2023 
           | 
        
| Journal | 
   The Journal of clinical investigation 
           | 
        
| Volume | 
   133 
           | 
        
| Issue | 
   4 
           | 
        
| Date Published | 
   03/2023 
           | 
        
| ISSN Number | 
   1558-8238 
           | 
        
| DOI | 
   10.1172/JCI156722 
           | 
        
| Alternate Journal | 
   J Clin Invest 
           | 
        
| PMCID | 
   PMC9927931 
           | 
        
| PMID | 
   36512408 
           | 
        
| Download citation |